Introduction to the drug Platinib (Pujihua) and its application progress in the field of targeted therapy

Pralsetinib is an oral small molecule targeted drug that is a RETtyrosine kinase inhibitor. It mainly blocks the proliferation and survival signals of tumor cells by selectively inhibiting the RET fusion gene and mutant RETkinase activity. The drug is highly selective and well tolerated in molecular targeted therapy, and has shown significant efficacy in RET-driven non-small cell lung cancer (NSCLC), papillary thyroid cancer (PTC) and other RET-positive solid tumors.

Platinib has demonstrated breakthrough efficacy in RET driven tumors. Clinical studies have shown that for patients with RETfusion-positive NSCLC who have progressed despite multiple treatment regimens, platinib can It can significantly improve the objective response rate (ORR) and progression-free survival (PFS), providing a new treatment option for these patients. Compared with traditional chemotherapy, Platinib's targeting properties make its side effects more controllable and improve patients' quality of life.

With the advancement of multiple Phase II and III clinical trials, the indications of Platinib in different types of RET driven tumors continue to expand. For example, for patients with papillary thyroid cancer and metastatic RET-positive tumors, platinib has shown high efficacy and tolerability, making it one of the few precision targeted therapies targeting RET mutations. In addition, domestic and foreign pharmaceutical companies are also exploring its application potential in combination with immunotherapy or other targeted drugs to further improve the efficacy.

Platinib, as a RET targeted drug, has broad prospects in the field of precision medicine and personalized treatment. With the popularization of genetic testing technology, more RET positive patients can be identified early and benefit from this drug treatment. Future research will focus on strategies to optimize dosage regimens, reduce the risk of adverse reactions, and combine with other targeted or immunotherapies to further promote the clinical application and development of RET targeted therapies.

Reference link:https://www.drugs.com